Physician profile
Cameron L Budenz
NPI 1679609465
$3,485.17
in general payments reported to CMS, 2019-2025
35 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $596 · 2021: $391 · 2022: $720 · 2023: $686 · 2024: $406 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $617.06 | 2019-2025 | |
| Csl Behring | $296.33 | 2020-2025 | Hizentra, Andembry, Haegarda |
| Pharming Healthcare, INC. | $280.37 | 2020-2025 | Ruconest |
| Genzyme Corporation | $266.60 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.41 | 2020-2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $242.33 | 2019-2025 | |
| Glaxosmithkline, LLC. | $230.11 | 2019-2023 | Nucala |
| Cochlear Americas | $145.87 | 2021-2023 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Astrazeneca Pharmaceuticals LP | $96.55 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $96.05 | 2022-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $91.99 | 2020-2023 | Dupixent |
| Hikma Pharmaceuticals USA | $77.07 | 2023-2024 | Ryaltris |
| Stryker Corporation | $75.31 | 2019-2025 | Audion Et Dilation System, Xpress Loprofile, Scopis Ent |
| Kaleo, INC. | $71.69 | 2020-2023 | Auvi-Q |
| Neurent Medical Limited | $53.83 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $50.63 | 2024-2025 | Xolair |
| Integra Lifesciences Corporation | $45.72 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Medtronic, INC. | $44.97 | 2024 | Propel |
| Smith+Nephew, INC. | $44.02 | 2024-2025 | Halo, Tula, Coblation |
| Acclarent, INC | $43.86 | 2020 | |
| Pfizer INC. | $40.31 | 2020 | |
| Alk-Abello, INC | $39.21 | 2020-2021 | |
| Precigen, INC. | $33.55 | 2025 | |
| Incyte Corporation | $28.27 | 2023 | Opzelura |
| Ionis Pharmaceuticals, INC. | $27.04 | 2025 | Dawnzera |
| Lilly USA, LLC | $25.85 | 2025 | Zepbound |
| Phathom Pharmaceuticals, INC. | $24.38 | 2024 | Voquezna |
| Bio Products Laboratory USA, INC. | $23.66 | 2020 | |
| Paratek Pharmaceuticals, INC. | $22.81 | 2025 | Xhance |
| Shire North American Group INC | $20.31 | 2019 | |
| Cook Medical LLC | $17.37 | 2019 | |
| Med-El Corporation | $16.25 | 2023 | Mi1250 Synchrony 2 Flexsoft |
| Merck Sharp & Dohme LLC | $15.71 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.68 | 2020 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Budenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.